Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Short description of key information on bioaccumulation potential result:
Uptake via inhalation is not anticipated for NOM, while dermal absorption is feasible. Significant accumulation in fatty tissue is highly unlikely.
Key value for chemical safety assessment
Additional information
The natural oil monomer consists of esters of the fatty acids palmitic acid (C16), margaric acid (C17) and stearic acid (C18), and C16-C18 fatty acids with one or more methanol side groups on the chain. The methyl groups are likely to hydrolyse readily. Palmitic and stearic acid are endogenous compounds and are present in abundance in our food. Margaric acid is a naturally occurring dietary fat present in our food, but this fatty acid is not synthesized by the human body.
The fatty acids are anticipated to be distributed, metabolized and excreted in the same way as naturally occurring fatty acids. Fatty acids with an additional methanol side group are expected to follow these same pathways, with the additional potential for Phase II conjugation of the methanol moieties of these components. Significant accumulation in fatty tissue is highly unlikely. The anticipated toxicokinetic behaviour of NOM is consistent with the low toxicity of the substance.
Discussion on absorption rate:
Dermal uptake for NOM is possible. Conversely, fatty acids and fatty acid methyl esters are used as penetration enhancers for drug delivery (Chukwumerije et al., 1989; Kogan and Garti, 2006) and thus, it is expected that the fatty acid properties of MPS would allow for dermal penetration. Consistent with the uses for drug delivery, dermal absorption of fatty acids are generally regarded as safe, and the toxicity profile of MPS following dermal testing is consistent with this as well. The dermal absorption of MPS has not been studied to date. However, the permeability of this compound through skin can be estimated with QSAR programs, such as the DermWin model from the US EPA. Using this application, the steady-state flux of a 1% solution of MPS through skin is estimated to be 0.65-240 mg/cm2 surface area of skin, for the various components. The calculated Kp, or rate of penetration via the DermWin model, is calculated to be 1.28-24.4 cm/hr.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
